- Home
- BDRX
as 11-15-2024 4:00pm EST
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
| Founded: | 2000 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 3.4M | IPO Year: | N/A |
| Target Price: | $200.00 | AVG Volume (30 days): | 55.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -45.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.51 - $220.25 | Next Earning Date: | 11-26-2024 |
| Revenue: | $104,895 | Revenue Growth: | -84.31% |
| Revenue Growth (this year): | -91.09% | Revenue Growth (next year): | -49.98% |
Latest Biodexa Pharmaceuticals plc American Depositary Shs News
BDRX Breaking Stock News: Dive into BDRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq
GlobeNewswire
10 days ago
Notice of General Meeting
ACCESSWIRE
a month ago
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer
GlobeNewswire
a month ago
Biodexa Announces Successful Appeal of Nasdaq Delisting
GlobeNewswire
a month ago
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma
GlobeNewswire
2 months ago
Interim results for the six months ended June 30, 2024
GlobeNewswire
2 months ago
ADR Ratio Change
GlobeNewswire
2 months ago
Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant
Compare BDRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BDRX Biodexa Pharmaceuticals plc American Depositary Shs - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.